The suppressive effects of gx-50 on Aβ-induced chemotactic migration of microglia.

Int Immunopharmacol

School of Life Science and Biotechnology, Shanghai Jiao Tong University, No. 800, Dongchuan Road, Minhang District, Shanghai 200240, China. Electronic address:

Published: April 2014

Microglia, the main immune cells of the central nervous system (CNS), play a vital role in the development of AD. Once microglia are activated, they migrate to neuritic plaques and persistently release pro-inflammatory mediators that lead to neuroinflammation and neuronal degeneration, accelerating the progression of AD. In this study, we analyzed whether an AD candidate drug, N-[2-(3,4-dimethoxyphenyl)ethyl]-3-phenyl-acrylamide (gx-50), a compound extracted from Sichuan pepper (Zanthoxylum bungeanum), exhibited suppressive effects on the chemotactic migration of microglia induced by Aβ. At first, the effects of gx-50 on the migration of primary cultured microglia to Aβ were detected by transwell assay, and the secretion of chemokine CCL5 was measured by ELISA assay. Then, the release of TGF-β1 was detected by ELISA and quantitative real-time PCR, and the activation of the TGF-β1-Smad2 pathway was analyzed by Western blotting. The LDH assay revealed that cell viability was not affected by gx-50 at concentrations from 0.01 to 100 μM; thus, combined with our previous studies, 1 μM was chosen as the treatment concentration. The cell transwell measurement demonstrated that gx-50 suppressed the chemotactic migration of microglia by nearly 50% and inhibited the increase in CCL5 triggered by Aβ. Moreover, the analysis of the TGF-β1-Smad2 pathway revealed that gx-50 can antagonize Aβ-induced down-regulation of TGF-β1 at both the mRNA and protein levels and stimulate the signal pathway activation. Simultaneously, gx-50 pretreatment also significantly enhanced the phosphorylation of glycogen synthase kinase-3β (GSK-3β), which correlated closely with the migration of microglia. In conclusion, in the presence of Aβ, gx-50 pretreatment inhibited the excessive chemotactic migration of microglia.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2014.01.025DOI Listing

Publication Analysis

Top Keywords

migration microglia
20
chemotactic migration
16
suppressive effects
8
gx-50
8
effects gx-50
8
microglia
8
tgf-β1-smad2 pathway
8
gx-50 pretreatment
8
migration
6
gx-50 aβ-induced
4

Similar Publications

Background: Genome-wide association studies (GWAS) identified the ATP binding cassette subfamily A member 7 (ABCA7) gene as increasing risk for Alzheimer's disease (AD). ABC proteins transport various molecules across extra and intra-cellular membranes. ABCA7 is part of the ABC1 subfamily and is expressed in brain cells including neurons, astrocytes, microglia, endothelial cells and pericytes.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) hallmarks are amyloid plaques and tau tangles. APOE and TREM2 are the strongest genetic risk factors for AD. Triggering receptor expressed on myeloid cells 2 (TREM2) is increasingly recognized to play a central role in amyloid beta clearance and microglia activation in AD.

View Article and Find Full Text PDF

Background: Amyloid-beta (Aβ) deposition is a key pathological characteristic of Alzheimer's disease (AD). Microglia serves as a crucial system responsible for clearing Aβ. Activated microglia migrate towards Aβ deposits, engulf them, and breakdown Aβ through cathepsins within the lysosome.

View Article and Find Full Text PDF

Background: Neurodegenerative disorders such as Alzheimer's Disease (AD) are increasingly associated with irregular lipid accumulation. Dysfunction in the catabolism of sphingolipids leads to many neurodegenerative disorders but has only recently garnered interest in AD. Excess ceramide deposition has been observed in Aβ-plaques, plasma, and cerebrospinal fluid in AD patients and AD mouse models.

View Article and Find Full Text PDF

Background: The aggregation of α-synuclein protein, encoded by the SNCA gene, forms Lewy bodies (LBs) in neurons and is a key pathological feature of Lewy body dementia (LBD). Interestingly, the apolipoprotein E gene (APOE), primarily expressed in glial cells, is the strongest genetic modifier for LBD. The ε4 allele of this gene (APOE4) notably increases the risk of LBD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!